Phase 4
Completed N=93
Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction
Source: ClinicalTrials.gov NCT01225952 ↗Enrolled (actual)
93
Serious AEs
0.0%
Results posted
Jan 2013
Primary outcomePrimary: Monocular Mesopic Contrast Sensitivity Without Glare (1.5, 3 Cycles/Degree) — 1.612; 1.582; 1.527; 1.658 log contrast sensitivity units
Summary
The objective of this study is to compare the contrast sensitivity, high and low contrast visual acuity (VA), glare meter outcomes, and subject satisfaction with three different FDA-approved intraocular lenses (IOLs) designed to improve distance, intermediate, and near vision following lens extraction in adults at least 40 years of age.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Monocular Mesopic Contrast Sensitivity Without Glare (1.5, 3 Cycles/Degree) |
1.612; 1.582; 1.527; 1.658; 1.627; 1.629 | — |
| PRIMARY Monocular Mesopic Contrast Sensitivity Without Glare(6 Cycles/Degree) |
1.579; 1.499; 1.610 | — |
| PRIMARY Monocular Mesopic Contrast Sensitivity Without Glare(12 Cycles/Degree) |
1.280; 1.225; 1.230 | — |
| PRIMARY Monocular Mesopic Contrast Sensitivity Without Glare(18 Cycles/Degree) |
0.974; 0.980; 0.976 | — |
| PRIMARY Monocular Mesopic Contrast Sensitivity Without Glare(1.5, 3 Cycles/Degree) |
1.696; 1.621; 1.527; 1.678; 1.670; 1.630 | — |
| SECONDARY Binocular Mesopic Contrast Sensitivity Without Glare(1.5, 3 Cycles/Degree) |
1.797; 1.751; 1.577; 1.851; 1.723; 1.702 | — |
| SECONDARY Binocular Mesopic Contrast Sensitivity Without Glare(6 Cycles/Degree) |
1.758; 1.640; 1.690 | — |
| SECONDARY Binocular Mesopic Contrast Sensitivity Without Glare(12 Cycles/Degree) |
1.371; 1.269; 1.310 | — |
| SECONDARY Binocular Mesopic Contrast Sensitivity Without Glare(18 Cycles/Degree) |
1.115; 0.995; 1.041 | — |
| SECONDARY Monocular Mesopic Contrast Sensitivity With Glare(1.5 Cycles/Degree) |
1.550; 1.488; 1.449 | — |
| SECONDARY Monocular Mesopic Contrast Sensitivity With Glare (3 Cycles/Degree) |
1.687; 1.581; 1.588 | — |
| SECONDARY Monocular Mesopic Contrast Sensitivity With Glare(6 Cycles/Degree) |
1.578; 1.493; 1.519 | — |
| SECONDARY Monocular Mesopic Contrast Sensitivity With Glare(12 Cycles/Degree) |
1.335; 1.246; 1.194 | — |
| SECONDARY Monocular Mesopic Contrast Sensitivity With Glare(18 Cycles/Degree) |
0.919; 1.019; 0.935 | — |
| SECONDARY Monocular Mesopic Contrast Sensitivity With Glare(3 Cycles/Degree) |
1.664; 1.572; 1.535 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects must be undergoing primary IOL implantation for the correction of aphakia following continuous curvilinear anterior capsulotomy and phacoemulsification cataract extraction.
- Subjects must require a spherical lens power from 10.00 diopters (D) to 33.00 D.
- Subjects must have the potential for corrected distance visual acuity (CDVA) of 20/32 or better in both eyes.
- Subjects must have stopped contact lens wear for at least two weeks for soft lens wearers or three weeks for gas permeable lens wearers prior to biometry and surgery.
- At the time of surgery, subjects must have an intact centered capsulorhexis, intact posterior capsule, and no zonular rupture.
- Subjects must have ≤ 1.25 D of preoperative corneal astigmatism in both eyes.
Exclusion Criteria
- Subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or other retinal disorders) that cause potential acuity losses to a level of 20/32 or worse.
- Subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome.
- Subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis.
- Subjects with uncontrolled glaucoma.
- Subjects with previous retinal detachment.
- Subjects with visually significant diabetic retinopathy (proliferative or nonproliferative) which reduces potential acuity to 20/32 or worse.
- Subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract.
- Subjects with marked microphthalmos or aniridia.
- Subjects who have had previous corneal surgery.
- Subjects with irregular corneal astigmatism.
- Subjects with amblyopia which reduces potential acuity to 20/32 or worse.
- Subjects with optic atrophy.
- Subjects with iris neovascularization.
- Subjects with clinically significant retinal pigment epithelium/macular changes which reduces potential acuity to 20/32 or worse.
- Subjects with chronic use of systemic steroids or immunosuppressive medications.
Data sourced from ClinicalTrials.gov (NCT01225952). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.